12 December
2024
AOTI, INC. (the "Company" or
"Group" or "AOTI")
AOTI Awarded Five Year
Extension To Veterans Administration Contract
AOTI, INC., a medical technology
group focused on the durable healing of wounds and prevention of
amputations, is pleased to announce that it has been awarded
another five-year extension to its Federal Supply Schedule (FSS)
contract for its Topical Wound Oxygen (TWO2®)
therapy and NEXA NPWT products by the U.S. Department of Veterans
Affairs (VA).
The Veterans Health Administration
is America's largest integrated health care system, providing care
at 1,380 health care
facilities, including 170
medical centers and 1,193 outpatient sites of care, serving 9.1
million enrolled veterans each year.
The VA FSS programme supports the
healthcare requirements of the VA and other federal Government
agencies by negotiating contracts with pre-approved vendors for
fixed most favoured customer pricing, providing them access to
medical equipment, supplies, pharmaceutical, and service programmes
that totalled over $18.9 billion during fiscal year
2023.
The Company's FSS contract is now
active through to 14 June 2029, enabling AOTI to continue to
provide its multi-modality TWO2® therapy and
NEXA NPWT products to clinicians and veterans within the VA and
other federal healthcare programmes. The Company was first awarded
an FSS contract in 2009 and has since treated thousands of veterans
across the US, with its unique TWO2® therapy,
which is differentiated from all other wound treatment modalities
by its clinically proven ability to more durably heal wounds, save
limbs and reduce costs.
Dr.
Mike Griffiths, Chief Executive Officer and President of AOTI,
INC., commented: "We have proudly served the
veteran community for over 15 years. We are delighted to be awarded
a new five-year extension to our contract which has consistent
pricing and some improved terms, allowing us to continue to
strengthen our effective partnership. Promoting health equity and
addressing outcome disparities in patients with non-healing wounds
is central to our mission at AOTI. Our unique
TWO2®
therapy has
revolutionised chronic wound healing by providing significant
reductions in wound related reoccurrence, hospitalisations and
amputations1,2. With TWO2®
therapy being
primarily applied by veterans at home, we are driving meaningful
improvements in access-to-care for those who need it
most."
1. Multinational, Multicenter,
Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate
the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the
Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert
G. Frykberg et al, Diabetics Care 2020; 43:616-624.
https://doi.org/10.2337/dc19-0476.
2. Reduced Hospitalizations and
Amputations in Patients with Diabetic Foot Ulcers Treated with
Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World
Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care
2022; http://doi.org/10.1089/wound.2021.0118
END
AOTI, INC.
Dr. Mike Griffiths, Chief Executive
Officer
Jayesh Pankhania, Chief Financial
Officer
|
+44 (0)20 3727 1000
ir@aotinc.net
|
Peel Hunt LLP (Nominated Adviser and Broker)
Dr. Christopher Golden, Patrick
Birkholm
|
+44 (0)20 7418 8900
|
FTI
Consulting (Financial PR & IR)
Ben Atwell, Simon Conway,
Natalie Garland-Collins, Alex
Davis
|
+44 (0)20 3727 1000
AOTI@fitconsulting.com
|
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and
is based in Oceanside, California, US and Galway, Ireland,
providing innovative solutions to resolve severe and chronic wounds
worldwide. Its products reduce healthcare costs and improve the
quality of life for patients with these debilitating conditions.
The Company's patented non-invasive Topical Wound Oxygen
(TWO2®) therapy has demonstrated in
differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably
reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in
an unprecedented 88 per cent reduction in hospitalisations and 71
per cent reduction in amputations over 12 months.
TWO2® therapy can be administered by the
patient at home, improving access to care and enhancing treatment
compliance. TWO2® therapy has received
regulatory clearance from the US (FDA), Europe (CE Mark), UK
(MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. Also
see www.aotinc.net